Change is afoot at AmerisourceBergen. The company announced its intent to change its name to Cencora as a way to better reflect its bold vision and purpose-driven approach to creating healthier futures.
The new name represents a unified presence that will continue to fuel the company’s ongoing growth strategy and advance its impact across health care, the company said.
"Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access, and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care," said Steven Collis, chairman, president and CEO of AmerisourceBergen.
AmerisourceBergen said that the name Cencora is inspired by customers and team members around the world. In addition, a shared identity will create a more inclusive experience for employees as well as a stronger employer brand to attract talent and increase employee loyalty, retention and performance. The name tells a compelling story, boldly differentiates the company, and was created with a future-oriented mindset.
AmerisourceBergen intends to begin operating as Cencora in the second half of the calendar year 2023, the company said.
The change to Cencora is aligned with the organization’s growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.
Operating as Cencora, a unified and internationally inclusive name and brand, the company will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform of pharma and biopharma services to support pharmaceutical innovation and access, the company concluded.